Huge July Employment Report: Analysts Upgrade or Downgrade Duke Energy, Paramount, Teva Pharmaceutical and More

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Huge July Employment Report: Analysts Upgrade or Downgrade Duke Energy, Paramount, Teva Pharmaceutical and More

© Bet_Noire / iStock via Getty Images

Markets turned lower to close out the week, despite a fairly strong employment report for July. The Nasdaq was leading the charge lower, down about 1%. The Dow Jones industrials were down 0.5%, and the S&P 500 was down 0.8%.

The July employment report that came out Friday morning topped consensus estimates across the board. The report’s big number, the nonfarm payrolls, came in at 528,000, crushing the consensus forecast of 250,000 and even June’s number of 398,000.

The unemployment rate came in at 3.5%, down slightly from June’s 3.6%. It is worth noting that this is the lowest unemployment rate that we have seen since February 2020, before the pandemic kicked off. Basically, this report demonstrated a return to pre-pandemic levels across the board.

It remains to be seen how the Federal Reserve will respond to these numbers, but for now it is definitely a stock-picker’s market.

[nativounit]

24/7 Wall St. is reviewing additional analyst calls seen on Friday. We have included the latest call on each stock, as well as a recent trading history and the consensus targets among analysts. Note that analyst calls seen earlier in the day were on Costco, Fortinet, Levi Strauss, Match, Robinhood and more.

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD | ACAD Price Prediction): Citigroup downgraded the stock to Neutral from Buy and cut its $19 price target to $15. The 52-week trading range is $12.24 to $28.06, and shares traded near $15 apiece on Friday.

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX): Oppenheimer’s downgrade was to Perform from Outperform, and the downgrade at Evercore ISI was from Outperform to In-Line with a $14 price target. The 52-week trading range is $7.61 to $19.99. Shares changed hands near $13 apiece on Friday.

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH): JMP Securities upgraded the shares to Outperform from Market Perform and has a $23 price target. The shares traded at around $16 on Friday. The 52-week trading range is $6.51 to $37.99 a share.

Duke Energy Corp. (NYSE: DUK): Credit Suisse lowered its Outperform rating to Neutral but raised its $112 price target to $114. The 52-week trading range is $95.48 to $116.33, and the share price was near $109 Friday.

[recirclink id=1158915]

Kellogg Co. (NYSE: K): Piper Sandler lifted its Neutral rating to Overweight with a $74 price target. The 52-week trading range is $59.54 to $76.45. The stock traded near $74 on Friday.

Paramount Global (NASDAQ: PARA): J.P. Morgan downgraded the stock to Underweight from Neutral and has a $25 price target. The 52-week trading range is $23.15 to $42.17, and shares were trading near $24 on Friday.

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM): The BofA Securities upgraded to Neutral from Underperform a price target hike from $8 all the way to $20. The stock traded near $18 on Friday. The 52-week trading range is $3.04 to $19.24.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA): As BofA Securities upgraded the shares to Buy from Neutral, it also raised the $10 price target to $13. The stock traded near $10 on Friday, in a 52-week range of $6.78 to $10.50.

[wallst_email_signup]
We are in one of the worst economic periods in America in decades, so buying stocks that will pay big, dependable dividends until the mess is sorted out continues to make sense. Seven stocks offer investors outstanding entry points and are Buy rated at top Wall Street firms.

Also see which five semiconductor stocks are poised to benefit from the U.S. CHIPS Act, three fresh stock picks with big upside potential and the three hot stocks investors may want to sell right away.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618